EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil
Introduction: Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to 10% in men younger than 40 years and up to 100% in men in their 70s and 80s. Aim: To evaluate the real-life characteristics and unmet needs of men with ED, its impact on well-being, and treat...
Main Authors: | Giovanni Corona, MD, PhD, Mario Maggi, MD, PhD, Emmanuele A. Jannini, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press
2018-03-01
|
Series: | Sexual Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2050116117300831 |
Similar Items
-
Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial
by: Hui Jiang, MD, PhD, et al.
Published: (2021-06-01) -
The Efficacy and Safety of Avanafil During a Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Warli SM, et al.
Published: (2023-07-01) -
Effect of PDE 5 Inhibitor-Avanafil on Renal Ischemia/Reperfusion Injury in Rats
by: Tuğba Nurcan YÜKSEL, et al.
Published: (2023-09-01) -
Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
by: Tomoya Kataoka, PhD, et al.
Published: (2022-04-01) -
REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome
by: Ridwan Shabsigh, MD, FACS, et al.
Published: (2016-09-01)